Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 9/2021

Open Access 01-09-2021 | Osteoporosis | Original Article

Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada

Authors: J.-É. Tarride, J. D. Adachi, J. P. Brown, E. Schemitsch, L. Slatkovska, N. Burke

Published in: Osteoporosis International | Issue 9/2021

Login to get access

Abstract

Summary

Using a matched cohort design, the 1-year excess cost of incident fragility fractures at any site was $26,341 per patient, with 43% of total excess costs attributed to hospitalization. The high economic burden of fractures in Ontario underscores the urgency of closing the secondary fracture prevention gap.

Introduction

This retrospective real-world observational study was conducted to document the incremental costs associated with fragility fractures in Ontario, Canada.

Methods

Patients aged >65 years with an index fragility fracture occurring between January 2011 and March 2015 were identified from administrative databases and matched 1:1 to a cohort of similar patients without a fracture. Healthcare resource utilization data were extracted from healthcare records and associated costs were calculated on a per-patient level and for the province of Ontario. Costs were presented as 2017 Canadian dollars.

Results

The eligible cohort included 115,776 patients with a fragility fracture. Of these, 101,773 patients were successfully matched 1:1 to a non-fracture cohort. Overall, hip fractures (n = 31,613) were the most common, whereas femur fractures (n = 3002) were the least common type. Hospitalization and continuing care/home care/long-term care accounted for more than 60% of 1-year direct costs, whereas 5% was attributed to medication costs. First-year costs per patient in the fracture cohort were approximately threefold higher versus the non-fracture cohort (mean $37,362 versus $11,020, respectively). The incremental first-year direct healthcare costs of fragility fractures for the province of Ontario were calculated at $724 million per year.

Conclusions

Fragility fractures were associated with a threefold increase in overall mean healthcare costs per patient compared to patients without fractures. With an aging population, there is an urgent need for improved prevention strategies for patients at high-risk of fracture to decrease the economic burden of fragility fractures on the Canadian healthcare system.
Appendix
Available only for authorised users
Literature
1.
Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733CrossRef
2.
Oden A, McCloskey EV, Kanis JA, Harvey NC, Johansson H (2015) Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int 26:2243–2248CrossRef
3.
Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427CrossRef
4.
Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465–475CrossRef
5.
Borgström F, Karlsson L, Ortsäter G, Norton N, Halbout P, Cooper C, Lorentzon M, McCloskey EV, Harvey NC, Javaid MK, Kanis JA, IOF (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15:59
6.
Rousculp MD, Long SR, Wang S, Schoenfeld MJ, Meadows ES (2007) Economic burden of osteoporosis-related fractures in Medicaid. Value Health 10:144–152CrossRef
7.
Adeyemi A, Delhougne G (2019) Incidence and economic burden of intertrochanteric fracture: a medicare claims database analysis. JB JS Open Access 4:e0045CrossRef
8.
Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M (2011) Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom. J Med Econ 14:99–107CrossRef
9.
Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Gitlin M, Robbins S (2012) Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom. Bone 51:324–331CrossRef
10.
De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10:66–72CrossRef
11.
Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY (2006) The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects. Osteoporos Int 17:1346–1352CrossRef
12.
Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, al-Daghri N, Bruyère O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30:45–57CrossRef
13.
Tarride JE, Hopkins RB, Leslie WD, Morin S, Adachi JD, Papaioannou A, Bessette L, Brown JP, Goeree R (2012) The burden of illness of osteoporosis in Canada. Osteoporos Int 23:2591–2600CrossRef
14.
Hopkins RB, Tarride JE, Leslie WD, Metge C, Lix LM, Morin S, Finlayson G, Azimaee M, Pullenayegum E, Goeree R, Adachi JD, Papaioannou A, Thabane L (2013) Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporos Int 24:581–593CrossRef
15.
Nikitovic M, Wodchis W, Krahn M, Cadarette S (2013) Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int 24:659–669CrossRef
16.
Hopkins RB, Burke N, Von Keyserlingk C, Leslie WD, Morin SN, Adachi JD, Papaioannou A, Bessette L, Brown JP, Pericleous L, Tarride J (2016) The current economic burden of illness of osteoporosis in Canada. Osteoporos Int 27:3023–3032
17.
18.
Avis D, Davis B, Steele JM (1988) Probabilistic analysis of a greedy heuristic for euclidean matching. Probab Eng Inf Sci 2:143–156CrossRef
19.
Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I (2013) Guidelines on person-level costing using administrative databases in Ontario. Working Paper Series. Vol 1. Toronto: Health System Performance Research Network.
20.
Leslie WD, Lix LM, Finlayson GS, Metge CJ, Morin SN, Majumdar SR (2013) Direct healthcare costs for 5 years post-fracture in Canada: a long-term population-based assessment. Osteoporos Int 24:1697–1705
21.
Haentjens P, Autier P, Barette M, Boonen S, Belgian Hip Fracture Study Group (2001) The economic cost of hip fractures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. J Bone Joint Surg Am 83:493–500
22.
Brown JP, Adachi JD, Schemitsch E, Tarride JE, Brown V, Bell A, Reiner M, Oliveira T, Motsepe-Ditshego P, Burke N, Slatkovska L (2021) Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario. BMC Musculoskelet Disord 22:105CrossRef
23.
Metadata
Title
Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada
Authors
J.-É. Tarride
J. D. Adachi
J. P. Brown
E. Schemitsch
L. Slatkovska
N. Burke
Publication date
01-09-2021
Publisher
Springer London
Published in
Osteoporosis International / Issue 9/2021
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-021-05877-8

Other articles of this Issue 9/2021

Osteoporosis International 9/2021 Go to the issue

Original Article

Serum non-esterified fatty acid levels and hip fracture risk: The Cardiovascular Health Study

Original Article

Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis

Original Article

Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis

Retraction Note

Retraction Note to: Comment on an article: “Osteoporosis in the age of COVID-19 patients”

Original Article

Predictive modeling of hypophosphatasia based on a case series of adult patients with persistent hypophosphatasemia

Review

Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies